<DOC>
	<DOCNO>NCT00798772</DOCNO>
	<brief_summary>Infection human immunodeficiency virus ( HIV ) cause decline immunity ability fight infection progress acquire immunodeficiency disease ( AIDS ) . Anti-HIV drug treatment improve prognosis person HIV infection , expensive potentially toxic . Low micronutrient level occur blood even early stage HIV infection increase risk poor prognosis , role micronutrient antioxidant supplement medical management HIV/AIDS well define . The proposed clinical trial aim assess supplementation untreated HIV-infected adult micronutrient antioxidant preparation delay decline immunity disease progression start anti-HIV drug treatment compare supplementation standard multivitamin . If finding positive , study implication health health care saving .</brief_summary>
	<brief_title>Micronutrients Antioxidants HIV Infection</brief_title>
	<detailed_description>Background : Antiretroviral therapy ( ART ) improve prognosis person human immunodeficiency virus ( HIV ) infection , expensive potentially toxic . Micronutrient deficiency occur even early stage HIV infection increase risk morbidity , disease progression acquire immunodeficiency syndrome ( AIDS ) mortality , role micronutrient antioxidant supplement medical management HIV/AIDS clear . Objective : To determine supplementation untreated asymptomatic HIV-infected person broad-spectrum micronutrient antioxidant preparation reduce rate decline CD4 T lymphocyte count , delay emergence document CDC-defined AIDS-defining illness , start ART compare 100 % recommend daily allowance ( RDA ) multivitamins mineral , safe . Study design : A prospective , randomize , control , double blind clinical trial supplementation 218 untreated asymptomatic HIV-infected adult micronutrient antioxidant preparation identical appear RDA multivitamin mineral two year , quarterly follow clinic assessment time baseline CD4 count &lt; 350 mm3 , emergence document CDC-defined AIDS-defining illness , start ART . Participants sample size : 218 participant clinic Ontario participate centre CIHR Canadian HIV Trials Network ( CTN ) . Study duration : approximately five year , allow approximately three year participant accrual two year follow-up . Eligibility criterion : The main eligibility criterion : • Asymptomatic HIV-infected adult least 18 year age • CD4+ cell ≥375 ≤750 cells/mm3 • No previous ART ( exclude less seven day perinatal transmission prophylaxis ) Study intervention : Oral supplementation broad spectrum micronutrient antioxidant preparation ( n=109 ) identical appear RDA multivitamin mineral ( n=109 ) . Primary outcome : Time baseline CD4+ cell count &lt; 350 cells/mm3 ( confirm two measure least one week apart ) , emergence document CDC-defined AIDS-defining illness , start ART Secondary outcome : • Non-AIDS related adverse event • Tolerance adherence study medication • Time baseline CD4+ cell count &lt; 350 cells/mm3 ( confirm two measure least one week apart ) • Time baseline emergence document CDC-defined AIDS-defining illness • Time baseline start ART • Serial quarterly lymphocyte measure : absolute lymphocyte count ( ALC ) , CD4+ , CD8+ , CD3+ cell count , CD4 % , CD8 % , CD4 : CD8 • Serial quarterly HIV RNA plasma viral load • Serum chemistry : Glucose , BUN , creatinine , total protein , C-reactive protein , albumin , alkaline phosphatase , ALT , AST , total bilirubin • Serum micronutrient level : Carotene ( quarterly ) vitamin B12 ( quarterly ) , folate ( six monthly ) vitamin D ( 25-OHD , six monthly ) • Quality Life measure : MOS HIV , EuroQol , Health Utilities Index ( HUI ) Statistical analysis : Analysis primary outcome intention-to-treat compare time baseline primary outcome . Interim analyse plan 100 participant follow one year .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Micronutrients</mesh_term>
	<mesh_term>Trace Elements</mesh_term>
	<mesh_term>Antioxidants</mesh_term>
	<criteria>asymptomatic HIV infect adult least 18 year age CD4+ cell 375 750 cells/mm3 receive ART ( exclude less seven day perinatal transmission prophylaxis ) woman child bear potential , negative pregnancy test within two week prior randomization agree practice barrier method birth control study willing able sign inform consent comply study protocol HIV2 infection alone know allergy intolerance study medication ingredient pregnant active treatment acute opportunistic infection malignancy ALT great 3 x normal range know cirrhosis liver serum creatinine le 133 umol/L abuse alcohol recreational drug take micronutrient ( except vitamin D* ) natural health product supplement within 30 day randomization *Maximum 2000 IU daily ( Health Canada Guidelines ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>Micronutrients</keyword>
	<keyword>Antioxidants</keyword>
</DOC>